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Abstract
Gastrointestinal stromal tumor (GIST) is a rare but an important clinical entity 
seen in our clinical practice. It is the most common mesenchymal tumor of the 
gastrointestinal tract and most common malignancy of the small intestine. 
Although the exact prevalence of GIST is not known, the incidence of GIST has 
been increasing. GISTs arise from interstitial cells of Cajal. Most of the GISTs 
occur due to mutation in c-kit gene or platelet derived growth factor receptor 
alpha gene. 15% of GISTs do not have these mutations and they are called wild-
type GISTs. Almost all GISTs express KIT receptor tyrosine kinase. Histologically, 
GISTs look like spindle cell tumors most of the time but they can be epitheloid or 
mixed type. The median size of GISTs varies from 2.7 cm to 8.9 cm. Clinically, 
patients with small GISTs remain asymptomatic but as the GIST size increases, 
patients present with various symptoms depending on the location of the GIST. 
Most of GISTs are located in the stomach or small bowel. Diagnosis is suspected 
on imaging and endoscopic studies, and confirmed by tissue acquisition with 
immunohistochemical staining. The aggressiveness of GISTs depends on the size, 
mitotic index and location. Surgical resection is the treatment of choice. But 
various endoscopic modalities of resection are increasingly being tried. Tyrosine 
kinase inhibitors are extremely useful in the management of large GISTs, 
unresectable GISTs and metastatic GISTs. Treatment options for metastatic GISTs 
also include radiotherapy, chemotherapy, hepatic artery embolization, 
chemoembolization and radiofrequency ablation.
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Core tip: Gastrointestinal stromal tumors are increasingly being diagnosed in our clinical 
practice with the availability of various imaging, endoscopic and endosonographic studies. 
Now we have better understanding of the pathophysiology of this tumor. A new tyrosine 
kinase inhibitor is now approved for the treatment of this tumor refractory to other agents 
in the same class. There is an increased interest in endoscopic resection of this tumor. 
Updated recommendation for the management of gastrointestinal stromal tumors will also 
be discussed in this review.
Citation: Ahmed M. Recent advances in the management of gastrointestinal stromal tumor. 




Gastrointestinal stromal tumors (GISTs) are rare gastrointestinal (GI) neoplasms 
accounting for 0.1 to 3% of all GI malignancies[1]. But they are the most common (80%) 
mesenchymal tumors of the GI tract[2]. They arise from the spindle shaped 
mesenchymal cells called interstitial cells of Cajal (ICCs) or stem cell precursors to 
these cells. ICCs are the GI pacemaker cells (specialized nerve cells) present in the 
muscularis propria and around the myenteric plexus. Most (50%-70%) of the GISTs are 
located in the stomach (70% in gastric body, 15% in antrum and 15% in cardia) or 
small intestine (30% in jejunum or ileum, 5% in duodenum) but they can arise in any 
part of the GI tract (colon, rectum, appendix together – 5% and esophagus 2%-3%), and 
rarely in the extra-GI site (mesentery, omentum, retroperitoneum and pancreas) where 
they arise from stem cell precursors to ICC[3]. The incidence of GISTs has been 
increasing over the last few decades. They generally occur in the middle aged and 
older population (median age 60-65 years) with slight male predominance (3:1)[4]. 
Patients may remain asymptomatic for long period of time until complication or 
metastasis occurs. Most of the time, GISTs are diagnosed incidentally in imaging 
studies, endoscopic evaluations, during surgical procedures or autopsy. Instead of 
classifying as benign or malignant, they are stratified as low risk and high risk GISTs 
depending on mitotic index, tumor size and tumor locations. They can have slow 
growing indolent course or fast growing, metastasizing and life threatening course. 
The prognosis can be excellent if they can be diagnosed and treated early. In the past, 
GISTs were thought to be originating from smooth muscles as they have smooth 
muscle features on light microscopy. In 1980s, they were named as stromal tumors as 
they were found to have no immunophenotypic features of smooth muscles on 
immunohistochemistry. In 1998, Kindblom and associates first reported that GISTs 
originated from ICCs[5]. In this article, the epidemiology, pathophysiology, histology, 
clinical aspects, diagnosis, the updated treatment strategy and prognosis of GISTs will 
be reviewed.
EPIDEMIOLOGY
In the United States (US), about 5000–6000 new cases of GISTs are diagnosed per 
year[6]. As per Surveillance, Epidemiology, and End Results database, the incidence of 
GIST increased from 0.55/100000 population in 2001 to 0.78/100000 population in 
2011[7]. Another study published in 2006 showed that there was 25-fold increase in 
incidence of GISTs in the US in 10 years since 1992[8]. In Europe, the incidence of GIST 
varies from 6.5 to 14.5 per million per year[9-11]. The exact of prevalence of GIST is not 
known. But it assumed that as many cases remain silent throughout their life, the 
prevalence of GISTs is possibly high. One German study on consecutive autopsies 
found the presence of subcentimeter GISTs in 22.5% of individuals older than 50 
years[12]. The real incidence of GIST is not known because a lot of tumors have not been 
tested for the KIT or the Platelet derived growth factor receptor alpha (PDGFRA) gene 
mutations.
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PATHOPHYSIOLOGY
Uncontrolled proliferation of ICCs leads to the development of GISTs. The c-kit proto-
oncogene located on chromosome 4q 11-12 encodes the transmembrane tyrosine 
kinase KIT[13]. The great discovery of gain-of-function mutation of c-KIT in human 
GISTs was published by Hirota et al[14] in 1998. Exon 11 (transmembrane domain) is 
involved in 90% of KIT gene mutation[15]. KIT-activating mutations lead to ICCs 
hyperplasia and GISTs. KIT gene mutation with constitutive activation of tyrosine 
kinase is found in 75% of GISTs. PDGFRA gene at chromosome 4q12 controls 
production of PDGFRA which is a part of a family of proteins called receptor tyrosine 
kinase (RTKs). The most common PDGFRA mutation is Asp842Val substitution in 
exon18. Intragenic activation mutation of PDGFRA gene with production of RTKs was 
found in about 35% of GISTs lacking KIT gene mutations[16]. Thus the growth of GISTs 
is propelled by mutation of either KIT gene (75% of cases) or PDGFRA gene (10% of 
cases). The oncogenic mechanisms appear to be alternative and mutually exclusive. 
GISTs associated with either KIT or PDGFRA gene mutations are indistinguishable 
with respect to cytogenetic changes associated with tumor progression. But GISTs 
associated with PDGFRA mutation due to Asp842Val substitution in exon18 is 
resistant to tyrosine kinase inhibitor (TKI) imatinib mesylate. About 15% of GISTs do 
not have detectable KIT or PDGFRA gene mutation. These are so-called ‘wild-type’ 
GISTs or pediatric GISTs. Wild-type GISTs should be tested for germ-line mutation in 
the SDH gene (SDH deficient by immunohistochemistry). Clinically, they cannot be 
distinguished from KIT or PDGFRA-mutant GISTs and have the same morphology, 
express high levels of KIT, and occur in any part of the GI tract[17]. Few other genetic 
mutations have been detected in wild-type GISTs. These include BRAF, HRAS, NRAS, 
PIK3CA gene mutations. Germline mutation of KIT or PDGFRA occurs in familial GIST 
which is extremely rare (< 0.1%) and autosomal dominant. Patients generally present 
in middle age of life with multiple GISTs. Familial GISTs have benign course and do 
not decrease life span[18]. GISTs can also be associated with certain syndromes. These 
include: (1) Neurofibromatosis type 1- multifocal small GISTs with low risk feature 
occur in small intestine. GISTs do not have KIT or PDGFRA mutation; (2) Carney-
Stratakis syndrome – SDH-deficient GIST and paraganglioma due to germline 
mutation of SDHA, SDHB, or SDHC [19]; and (3) Carney triad –gastric GISTs, 
paraganglioma and pulmonary chondromas. GISTs are multifocal with high local 
recurrence rate. The above syndromes lack KIT or PDGFRA gene mutation.
Immunohistochemistry is important to identify GISTs from other spindle cell or 
epitheloid tumors. GISTs are generally negative for desmin (smooth muscle marker) 
and S100 protein (Schwann cell marker) but can be variably positive for smooth 
muscle actin and muscle-specific actin[20]. 70% of GISTs stain positive for CD34 which 
was the first immunohistochemical marker identified in1984 to differentiate GIST from 
leiomyoma and leiomyosarcoma. CD117 (KIT) is a sensitive and more specific marker 
for GIST discovered in 1998[21]. DOG1 (a calcium-dependent chloride channel protein 
anoctamin) is a novel marker ubiquitously expressed in GISTs irrespective of KIT or 
PDGFRA mutation status[22]. It was first discovered in 2004. CD117 and DOG1 each 
stain positive in more than 95% of GISTs. KIT receptor tyrosine kinase is expressed by 
almost all GISTs[23]. It is not sufficient to establish the diagnosis of GIST just on the 
basis of immunohistochemical staining (IHS). Some extra-intestinal malignancies 
which can stain positive for KIT include small cell lung cancer, metastatic melanoma, 
angiosarcoma and Ewing’s sarcoma[24].
HISTOLOGY
GISTs are well-circumscribed tumors ranging in size from < 1 cm to > 40 cm in 
diameter, the median size varies from 2.7 cm (when diagnosed incidentally) to 8.9 cm 
(when a patient is symptomatic)[10,25]. Histologically, they are of 3 types: spindle cell 
type (70%), epitheloid type (20%) and mixed type (10%). Spindle cell types have 
compact and highly cellular spindle shaped cells which have fibrillary eosinophilic 
cytoplasm, ovoid nuclei with frequent paranuclear vacuolization, syncytial cell 
borders and are arranged in a storiform, fascicular pattern with minimal stroma. 
Dense deposits of collagen are also seen in the extracellular space. In epitheloid type, 
the cells have abundant pale eosinophilic to clear cytoplasms, round nuclei, distinct 
cellular borders and are arranged in sheets, nests or cords. Mixed types have 
combination of spindle cells and epitheloid cells. Rarely, GISTs contain acellular PAS 
stain positive collagen bundles known as skenoid fibers. Irrespective of the type, a 
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variable inflammatory infiltrate (lymphocytes and plasma cells), hemorrhage, necrosis 
and sclerosis can be present. Degeneration and necrosis can be seen in GIST histology. 
There can be complete absence or high mitotic activity[26,27]. Mitotic index calculated by 
counting the number of mitoses per 50 high-power fields is an important indicator of 
proliferative activity and prognosis of GIST.
Extragastrointestinal stromal tumors
Less than 5% of all GISTs are located outside the GI tract[28]. Most of the 
extragastrointestinal stromal tumors (EGISTs) are found in the mesentery or omentum 
but other sites of involvement include retroperitoneum, pancreas, spleen, falciform 
ligament, hepatogastric ligament, mediastinum and pelvis[29]. EGISTs are generally 
discovered during imaging studies and surgery. Tissue diagnosis is made by 
computerized tomography (CT)-guided or ultrasound-guided biopsy with IHS. They 
carry an aggressive course and poor prognosis if the GIST size is > 5 cm with mitotic 
rate of > 5/50 HPF.
Composite tumors with a GIST component
Coexistence of two different tumors i.e. collision tumors are extremely rare and 
generally detected in the surgically resected specimen. Collision tumors with 
coexistence of adenocarcinoma and GIST in the stomach and small intestine have been 
reported[30].
CLINICAL ASPECTS
As mentioned before, GISTs are now-a-days detected more and more by various 
imaging studies like CT, magnetic resonance imaging (MRI) and endoscopic 
ultrasound (EUS). Small GISTs do not produce any symptom or sign. But when they 
become larger in size, patients generally present with GI bleeding due to mucosal 
ulceration, abdominal pain or obstruction due to mass effect. In about 50% of cases, 
mucosal ulceration is seen on the luminal surface of the GIST[31]. Of course, symptoms 
and signs depend on the location of the tumor. Gastric GISTs may present with 
hematemesis, melena, dyspepsia, nausea, vomiting or early satiety. Duodenal GISTs 
are well-defined round or oval subepithelial masses, generally located in the second 
through the fourth part of duodenum. They do not cause duodenal obstruction or 
lymphadenopathy but they may cause bleeding, ampullary obstruction and jaundice. 
They may also metastasize frequently to the liver and peritoneum[32]. About 10% of 
gastric GISTs and 15% of duodenal GISTs may present emergently with upper GI 
bleeding. Small intestinal (jejunal – 40%, ileal - 60%) GISTs may present with small 
bowel bleeding, fatigue (due to anemia), abdominal pain and intestinal obstruction.
They cause acute abdominal symptoms more frequently than duodenal GISTs[33]. 
Esophageal GISTs may present with dysphagia. Mesenteric or omental GISTs may 
present as abdominal masses. 8% of GISTs may present with acute abdominal 
emergency due to bowel wall rupture and peritonitis[34]. Occasionaally tumor rupture 
into the peritoneal cavity may also cause intraabdominal bleeding and peritoneal 
seeding of tumor cells[35]. GISTs generally metastasize to the liver and intra-abdominal 
cavity but rarely they metastasize to the lungs and bones. Anorectal GISTs are well-
defined subepithelial tumors with an average size of 6.9 cm. They represent 5% of all 
GISTS. Most of the anorectal GISTs are asymptomatic, and are detected during 
endoscopic or imaging studies. Symptomatic patients may present with proctalgia 
(34%) or recal bleeding (25%)[36].
DIAGNOSIS
There is no supportive or confirmatory Laboratory test for GISTs. Imaging studies or 
endoscopic evaluations are done according to patient’s clinical presentation. As most 
of the GISTs occur in the stomach or small bowel, contrast-enhanced CT may show an 
intramural endophytic or exophytic (as GISTs generally involve the outer longitudinal 
muscular layer) hypervascular mass in the gastric or small bowel wall. Small (< 5 cm) 
GISTs are homogenous, smooth-walled and sharply margined masses whereas large 
(> 5 cm) GISTs are heterogenous (due to hemorrhage, necrosis or cystic degeneration) 
masses with well-defined or ill-defined margins and rare calcifications. CT is the most 
commonly used modality in the diagnosis of primary and metastatic GISTs. It is 
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helpful not only in the initial diagnosis but also in following the natural progression of 
GISTs and the response of GISTs to treatment[37]. On CT, GISTs are mainly iso to 
minimally hypodense to the muscle layer. In response to effective treatment, GISTs 
decreases in size and becomes more homogenous with disappearance of nodules. On 
the other hand, appearance of nodule in the GIST following treatment indicates 
recurrence of the disease. The main drawback of CT is inability to differentiate 
between inflammatory adhesions and involvement of contiguous organs. In case of 
gastric GISTs it is difficult to decide if the tumor arises from the stomach, pancreas, 
liver or colon. MRI is adjunctive to CT in the evaluation of GISTs. On MRI, small GISTs 
are generally round and homogenous with strong arterial enhancement while large 
GISTs are usually lobulated and mildly heterogenous with gradual enhancement due 
to hemorrhage, necrosis and cystic changes[38]. MRI is more useful in the evaluation of 
anorectal GISTs and metastatic hepatic GISTs. On MRI, GISTs are iso to minimally 
hypointense to the muscle layer on T1-weighted images and hyperintense on T2-
weighted images. More than 90% of GISTs are fluorodeoxyglucose (FDG) avid with a 
mean baseline standard uptake value of 5.8 on FDG-positron emission tomography 
(FDG-PET)[39]. A baseline FDG-PET should be done prior to initiation of therapy. It is 
an ideal test not only for staging of GISTs but also for assessing therapeutic response, 
evaluating primary and secondary resistance to treatment, and resolving discrepant 
findings between clinical status and CT results. Primary resistance to TKI therapy can 
be identified by seeing lack of metabolic response on FDG-PET shortly after initiation 
of therapy. Secondary resistance to TKI will show re-emergence of metabolic activity 
(hot spot) on a quiescent area within the GIST following a period of therapeutic 
response. Combined hybrid PET/CT scanning can be the optimal test for the 
evaluation of patients treated with TKI[40]. Endoscopically, GISTs appear as spherical or 
hemispherical smooth, subepithelial polypoid lesions which are further evaluated by 
EUS. Most commonly GISTs originate from the muscularis propria i.e., echo-poor 4th 
EUS layer of the GI wall but rarely they can originate from the echo-poor 2nd layer i.e., 
muscularis mucosae[41]. Endosonographically, they appear as inhomogeneous, 
hypoechoic lesions, their differential diagnoses include leiomyoma, lymphoma and 
schwannoma[42]. Tissue diagnosis should be done by EUS guided fine needle aspiration 
(FNA) for > 1 cm lesion or true cut biopsy (TCB) for 2 to 5 cm lesion, particularly if 
non-GIST histology like leiomyoma is suspected[43]. EUS-guided FNA/TCB should also 
be considered if it is a very large GIST needing neoadjuvant therapy with TKI. Tissue 
acquisition may not be necessary if it is a very large, symptomatic GIST with 
malignant features on EUS and has to be resected by surgery irrespective of FNA/TCB 
result. High risk malignant features on EUS include large size of the GIST (≥ 2 cm), 
irregular borders, presence of heterogenous echogenicity, anechoic (cystic) spaces, 
ulceration, echogenic foci, a marginal halo and increase in size during follow up[44,45]. 
Endoscopically, focal mucosal ulceration of the GIST is common and is not related to 
malignancy[46]. Endoscopic, endosonographic or imaging features are suggestive but 
not diagnostic of GIST. Histopatholgy with hematoxylin and eosin staining alone is 
not sufficient to establish the diagnosis of GIST. Definitive diagnosis of GIST is 
established when there is concordance between histology and IHS with KIT, CD34 or 
DOG1.
RISK STRATIFICATION OF GISTs
The aggressiveness of GISTs depends on the size and mitotic index of GISTs, and also 
anatomic site of involvement and patient’s age. As per the National Institute Health 
(NIH) GIST consensus criteria, GISTs are categorized into very low risk, low risk, 
intermediate risk and high risk groups as shown in Table 1[47].
As per NIH classification, 44% of GISTs belong to high-risk category, 24% 
intermediate risk and 32% low risk/very low risk category. The significance of mitotic 
index also depends on location of the GISTs. Small bowel, esophageal and rectal GISTs 
are more aggressive and are associated with worse prognosis and more recurrence 
than gastric GISTs of the same size, mitotic index and tumor rupture[48]. Size ≥ 10 cm, 
mitotic rate ≥ 5 per 50 HPF and location of the GIST (non-gastric) and tumor rupture 
can independently predict recurrence of the GIST after complete surgical resection[49]. 
A modified version of NIH risk assessment has been proposed by Joensuu as shown in 
Table 2. Currently, the Joensuu classification is widely used. Tumor size, mitotic index, 
primary tumor site and tumor rupture are included in this version. Patients belonging 
to high-risk category have 15%-20% risk of having recurrent disease[50]. Besides the 
above factors, certain mutations at the genetic level can be associated with poor 
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Table 1 National Institute Health gastrointestinal stromal tumor consensus criteria
Risk category Tumor size (cm) Mitotic count per 50 HPF
Very low risk < 2 < 5
Low risk 2-5 < 5
< 5 6–10Intermediate risk
5-10 < 5
>5 > 5
> 10 Any mitotic rate
High risk
Any size > 10
HPF: High power field.
Table 2 Joensuu criteria for gastrointestinal stromal tumor risk assessment
Risk category Tumor size (cm) Mitotic index (per 50 HPF) Primary tumor site
Very low < 2 ≤ 5 Any
Low 2.1-5 ≤ 5 Any
2.1–5 > 5 Gastric
< 5 6–10 Any
Intermediate
5.1-10 ≤ 5 Gastric
Any Any Tumor rupture
> 10 Any Any
Any > 10 Any
> 5 > 5 Any
2.1–5 > 5 Non-gastric
High
5.1-10 ≤ 5 Non-gastric
HPF: High power field.
outcome. These include KIT exon 9 mutations and deletions affecting codons 557-558 
(exon 11 deletions) of the c-KIT gene[51]. KIT exon 9 mutations are almost exclusively 
found in the small bowel. As mentioned before PDGFRA mutation due to Asp842Val 
substitution in exon18 leads to resistance to tyrosine kinase inhibitor imatinib 
mesylate. PDGFRA mutations are usually seen in gastric GISTs. A simplified way of 
stratifying the risk of GISTs is to use “rule of fives” for low risk and high risk 
groups[52]. Both high risk and intermediate risk gastric GISTs are > 5 cm in size and 
have > 5 mitosis per 50 HPF whereas non-gastric GISTs belong to high risk category if 
they are either > 5 cm in size or have > 5 mitosis per 50 HPF. Gastric GISTs < 10 cm 
and < 5 mitosis per HPF can metastasize in about 2 to 3% of cases whereas gastric 
GISTs > 10 cm and > 5 mitosis per 50 HPF can metastasize in about 86% of cases. 11% 
of gastric GISTs > 10 cm with < 5 mitosis per HPF and 15% of gastric GISTs < 5 cm 
with > 5 mitosis per 50 HPF can metastasize. Gastric antral GISTs carry a better 
prognosis than gastric fundic or gastroesophageal junction GISTs[53]. Small intestinal 
GISTs > 10 cm with mitosis ≤ 5 per 50 HPF or ≤ 5 cm with mitosis > 5 per 50 HPF have 
metastatic potential of > 50% whereas small intestinal GISTs > 5 to 10 cm with mitosis 
< 5 per 50 HPF have metastatic potential of 24%[54].
The latest staging system of GIST is the 2018 American Joint Committee of Cancer 
tumor node metastasis system as shown in Table 3 and Table 4[55].
Ahmed M. Recent advances in the management of GIST
WJCC https://www.wjgnet.com 3148 August 6, 2020 Volume 8 Issue 15
Table 3 American Joint Committee on Cancer tumor node metastasis system for gastric and omental gastrointestinal stromal tumor
Stage TNM Mitotic rate Stage description
IA T1 or T2; N0; M0 Low (G1): mitotic rate 5/50 per 
HPF or less
T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; N0: no regional lymph node 
metastasis; M0: No distant metastasis
IB T3; N0; M0 Low (G1) T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No 
distant metastasis
II T1; N0; M0 or T2; N0; 
M0 or T4; N0; M0
High (G2): mitotic rate > 5/50 
HPF; High (G2); or Low (G1)
T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; T4: Tumor > 10 cm in greatest 
dimension; N0: no regional lymph node metastasis; M0: No distant metastasis
IIIA T3; N0; M0 High (G2) T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No 
distant metastasis
IIIB T4; N0; M0 High (G2) T4: Tumor > 10 cm in greatest dimension; N0: no regional lymph node metastasis; 
M0: No distant metastasis
IV Any T; N1; M0 or Any 
T; Any N; M1
Any rate or Any rate N1: Regional lymph node metastasis; M1: Distant metastasis
TNM: Tumor node metastasis; HPF: High power field.
Table 4 American Joint Committee on Cancer tumor node metastasis system for small intestine, esophagus, colon, rectum, or 
peritoneum
Stage TNM Mitotic rate Stage description
I T1 or T2; N0; M0 Low (G1): mitotic rate 5/50 
per HPF or less
T1: Tumor ≤ 2 cm; T2: Tumor > 2 cm but ≤ 5 cm; N0: no regional lymph node metastasis; 
M0: No distant metastasis
II T3; N0; M0 Low (G1) T3: Tumor > 5 cm but ≤ 10 cm; N0: no regional lymph node metastasis; M0: No distant 
metastasis
IIIA T1; N0; M0 or T4; N0; 
M0
High (G2): mitotic rate > 
5/50 HPF; or Low (G1)
T1: Tumor ≤ 2 cm; T4: Tumor > 10 cm in greatest dimension; N0: no regional lymph node 
metastasis; M0: No distant metastasis
IIIB T2; N0; M0 or T3; N0; 
M0 or T4; N0; M0
High (G2); or High (G2); or 
High (G2)
T2: Tumor > 2 cm but ≤ 5 cm; T3: Tumor > 5 cm but ≤ 10 cm; T4: Tumor > 10 cm in greatest 
dimension; N0: no regional lymph node metastasis; M0: No distant metastasis
IV Any T; N1; M0 or Any 
T; Any N; M1
Any rate or Any rate N1: Regional lymph node metastasis; M1: Distant metastasis
TNM: Tumor node metastasis; HPF: High power field.
TREATMENT
The treatment of GISTs depends on risk stratification. The different therapeutic 
modalities of GISTs include surgery, endoscopic resection, medical therapy, 
radiotherapy, chemotherapy, hepatic artery embolization, chemoembolization and 
radiofrequency ablation.
SURGERY
Surgery is the treatment of choice for localized symptomatic GISTs, ≥ 2 cm GISTs and 
GISTs with suspicious EUS features of malignancy as mentioned before[56]. According 
to National Comprehensive Cancer Network (NCCN), asymptomatic patients with 
GISTs < 2 cm with benign EUS features can be followed conservatively with annual 
EUS and/or esophagogastroduodenoscopy[57]. But surgery should be considered if the 
GIST increases in size during follow-up. R0 resection (negative margin) of the GIST is 
the main aim of surgery. As GISTs almost never metastasize to the lymph nodes, 
routine local lymph node dissection is not necessary unless suspected on imaging or 
endosonography. The surgical approach depends on the location of the GIST, its 
adherence or invasion into adjacent structures and the patient’s general medical status. 
Laparoscopic surgery (wedge resection) is indicated if the GIST is less than 5 cm in 
size[58]. As GISTs are usually surrounded by a pseudocapsule, enucleation technique is 
tried for small posterior wall GIST of the stomach at the gastroesophageal junction or 
small esophageal GIST to preserve the organ’s function. Esophagectomy is done for 
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large esophageal GIST. Depending on the size, number and location of gastric GISTs, 
surgical options include wedge partial resection of the stomach, Biliroth I partial 
gastrectomy or gastroduodenostomy, Biliroth II partial gastrectomy or 
gastrojejunostomy and total gastrectomy with Roux-en-Y reconstruction. If the 
duodenal GIST is small and far enough away from the ampulla of Vater, segmental 
duodenal resection with end to end anastomosis can be done. But if the GIST is close to 
the ampulla of Vater or adherent to adjacent organs, pancreaduodenectomy or 
Whipple resection is required. In case of jejunal, ileal or colonic GISTs, segmental 
resection with anastomosis of the divided ends are done. Surgery for rectal GISTs 
depends on the location: if the GIST is in the upper rectum or not too close to the anal 
sphincter, rectal resection with anastomosis of the divided colonic end to the 
remaining rectum can be done with or without temporary colostomy. If the GIST is 
close to the anal sphincter, abdominoperineal resection of the rectum (resection of 
rectum and anus with permanent sigmoid colostomy) is done[59]. Novel techniques to 
remove rectal GISTs have been described. These include transanal endoscopic 
operation[60] and transanal minimal invasive surgery[61]. Appendiceal GISTs are 
extremely rare and treated by simple laparoscopic appendectomy.
Total 80% of the GISTs are single and surgery is considered as the first line therapy. 
But if the GIST is large in size and surgical resection can be difficult, shrinkage of the 
GIST can be done by giving TKI therapy (neoadjuvant therapy) prior to surgery. 
Sometimes, debulking surgery is also considered in case of potentially resectable 
metastatic GISTs. Surgery is also required emergently in case of bleeding gastric or 
duodenal GISTs.
ENDOSCOPIC RESECTION
Endoscopic treatment is mainly used for the treatment of GISTs of the upper GI tract 
for patients with no recurrence or metastasis[62]. The available endoscopic resection 
methods include endoscopic enucleation, endoscopic band ligation (EBL), endoscopic 
submucosal dissection (ESD), endoscopic submucosal excavation (ESE), submucosal 
tunneling endoscopic resection (STER), endoscopic full-thickness resection (EFTR), 
and laparoscopic and endoscopic cooperative surgery (LECS)[63-71]. Endo-
sonographically, gastric GIST can be classified into 4 types according to their location 
in the mucularis propria (MP). Type I GIST protrudes into the lumen like a polyp and 
is attached to the MP by a narrow connection. Type II GIST also protrudes into the 
lumen but is attached to the MP by a wider connection. Type III GIST is centrally 
located in the gastric wall. Type IV protrudes outwards towards the serosa of the 
gastric wall[46]. Endoscopic enucleation can be done for type I and possibly for type II 
GISTs. Type III and type IV GISTs can be treated by other endoscopic methods which 
include EBL, ESD, ESE, STER, EFTR and LECs. Small (≤ 4 cm) gastric GISTs can be 
resected safely by endoscopic methods although intermediate or high risk GISTs may 
require adjuvant TKI therapy and/or additional surgery to reduce the chance of 
metastasis and recurrence[72].
MEDICAL THERAPY
Medical therapy includes TKIs which has revolutionized the treatment of metastatic 
and unresectable GISTs. TKI is given in patients with metastatic and unresectable 
GISTs as a definitive therapy. Metastatic lesion should be biopsied to confirm the 
diagnosis and mutational analysis should be assessed. Adjuvant therapy is given after 
surgery and continued for 3 years to decrease the chance of recurrence of GISTs with 
high (> 50%) risk of recurrence[73]. A prognostic nomogram was developed at the 
Memorial Sloan-Kettering Cancer Center for recurrence-free survival (RFS) after 
complete surgical resection of localized GISTs using tumor size (in cm), location 
(stomach, small intestine, colon/rectum, or other), and mitotic index (< 5 or ≥ 5 
mitoses per 50 high power fields). The nomogram is able to predict RFS for patients 
with completely resected GIST and can be used to select patients for adjuvant 
therapy[74]. Neoadjuvant therapy is given preoperatively for 6 to 12 mo (although the 
optimal duration is not known) in patients with large GISTs to decrease the size of the 
tumor to enable resectability. Neoadjuvant therapy should also be considered for 
organ and function-preserving surgeries like esophagectomy for esophageal GIST, 
pancreatoduodenectomy for duodenal GIST and abdominoperineal resection for rectal 
GIST[75]. PET/CT should be done one month after beginning neoadjuvant therapy to 
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evaluate response to the treatment. TKI is also recommended in case of tumor rupture 
during surgery and should be continued for at least 3 years to lifelong. Some authors 
also recommend neoadjuvant therapy when GISTs present emergently with acute 
upper GI bleeding[76]. There is no guideline on the post-operative management of 
patients who received neoadjuvant therapy. Patients with high-risk GISTs, TKI should 
be continued for several years. Imatinib is the first-line therapy Sunitinib, the second-
line and Regorafenib, the third-line TKI used as adjuvant and neoadjuvant therapy[77]. 
The effectiveness of TKI depends on KIT and PDGFRA mutation. 90% of GISTs 
containing KIT exon 11 mutation and 50% of GISTs containing KIT exon 9 mutation 
respond to imatinib. Dose escalation of TKI may be needed to improve response. 
GISTs containing KIT exon 13 and 14 mutation are sensitive to sunitinib. Regorafenib 
improves progression free survival for locally advanced and unresectable GISTs which 
do not respond to imatinib or sunitinib[78]. Recently, a new TKI known as Avapritinib 
has been added for unresectable/metastatic GISTs with PDGFRA exon 18 mutation, 
including PDGFRA D842V[79]. Avapritinib is also indicated in patients with GISTS 
which keep growing despite imatinib or other TKI therapy. So testing for KIT and 
PDGFRA gene mutation is suggested, particularly when medical therapy is going to be 
administered. Multi-disciplinary team with experience and expertise in GISTs should 
be involved prior to initiation of therapy. According to NCCN guideline, resectable 
GISTs with minimum morbidity should be resected and risk assessment should be 
evaluated on the pathology of the GISTs as shown in Table 5. Patients with significant 
risks of recurrence (intermediate or high risk depending on size, mitotic rate and 
location) should be given TKI therapy. Resectable GISTs with significant morbidity 
should be considered for preoperative TKI therapy to decrease surgical morbidity. 
Imaging should be done to evaluate treatment response. If the patient responds to TKI 
therapy, TKI should be continued and surgery should be done. If the GIST progresses 
on TKI therapy, surgery should be done if feasible, but if surgery is not feasible: (1) For 
limited progression – (a) continue TKI (imatinib or avapritinib) and consider other 
options like resection, if feasible or radiofrequency ablation (RFA), embolization, 
chemoembolization and palliative radiation therapy for bone metastasis; and (b) 
increase the dose of imatinib as tolerated or change to sunitinib. Imaging should be 
done to evaluate therapeutic response and patient adherence; and (2) For widespread 
progression – (a) increase the dose of imatinib as tolerated or change imatinib to 
sunitinib; (b) If GISTs progresses on sunitinib, then change to regorafenib; and (c) If 
GISTs progresses on regorafinib, change to avapritinib.
Imaging should be done to evaluate therapeutic response and patient adherence.
If GISTs keep progressing despite giving imatinib, sunitinib, regorafinib and 
avapritinib, other options include enrolling the patients into clinical trials, use systemic 
therapy and agents against GIST (sorafenib, nilotinib, pazopanib, everolimus plus TKI 
and dasatinib for patients with D842V mutation) based on limited data or to give best 
supportive care.
Small gastric GIST (< 2 cm) should be evaluated by EUS-guided FNA and imaging. 
If the GIST has high-risk features, complete resection should be done. But if there is no 
high-risk feature, periodic endoscopic and imaging surveillance should be done. 
Micro-GISTs (< 1 cm) are generally benign irrespective of their mitotic rate.
TREATMENT OF UNRESECTABLE, METASTATIC OR RECURRENT GISTs
Baseline imaging and percutaneous image guided biopsy should be appropriate to 
establish metastatic disease. Patient should be started on imatinib or avapritinib. 
Follow-up imaging should be done to evaluate for treatment response. Wang et al[80] 
did a single center analysis in which patients with advanced and metastatic/recurrent 
GISTs were given imatinib mesylate for a median period of 8.2 mo preoperatively and 
tumor shrinkage was observed in almost 30% of cases. If the response is good and the 
disease remains stable, continue imatinib or avapritinib, and surgery consult should be 
done to consider resection. If resection is not possible, continue imatinib or avapritinib. 
If the disease is progressive, dose escalation and change of TKI should be considered. 
If GISTs keep progressing despite giving imatinib, sunitinib, regorafinib and 
avapritinib, other options include to enroll the patients into clinical trials, use systemic 
therapy and agents against GIST (sorafenib, nilotinib, pazopanib, everolimus plus TKI 
and dasatinib for patients with D842V mutation) based on limited data or to give best 
supportive care.
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Table 5 Treatment options of resectable gastrointestinal stromal tumors
Resectable GISTs with minimum morbidity Resectable GISTs with significant morbidity
Resection followed by risk stratification on 
pathology: (1) Very low or low risk category – no 
TKI; and (2) Intermediate or high risk category - 
TKI.
Preoperative TKI: (1) If patient responds to TKI: continue TKI and proceed with surgery; and (2) If patient does not respond to TKI: surgery if feasible. If surgery not feasible: (a) For 
limited progression -options include radiofrequency ablation, embolization, chemoembolization, and palliative radiation; and (b) For widespread progression – increase the dose of 
imatinib as tolerated, If that fails – sunitinib followed by regorafinib followed by avapritinib should be tried. If GIST continues to progress despite TKIs, other options include clinical 
trials, systemic agents against GIST and best supportive care.
GIST: Gastrointestinal stromal tumor; TKI: Tyrosine kinase inhibitor.
FOLLOW UP AND SURVIVAL
There is no current guideline for follow up of patients who have undergone GIST 
resection to evaluate for recurrence or metastasis. Current practice is based on 
clinician’s opinion taking into account the tumor site, size and mitotic index[81]. The 
imaging modality and follow up interval varies from institution to institution. Very 
low risk category patients may not need routine follow up although the risk of 
recurrence is not zero. Low risk category patients can be followed up by doing CT scan 
every 6 mo for 5 years. Intermediate to high risk category patients should be more 
closely followed-up with CT scan every 3 to 4 mo for 3 years, then every 6 months for 
5 years, and then yearly[82]. PET/CT is more sensitive than CT in detecting response, 
resistance and recurrence following TKI therapy when it is used for neoadjuvant, 
adjuvant or definitive therapy[83].
The survival of patients with GIST depends on several factors which include risk 
category or stage of the GIST, the type of treatment patient received and recurrence of 
GIST after treatment. If the GIST is localized, the 5-year survival rate is 94%. It 
becomes 82% if there is local spread of the GIST. If the GIST has distant metastasis at 
the time of diagnosis, the 5-year survival rate becomes 52%[84].
SUMMARY
GISTs are well-circumscribed mesenchymal tumors (median size 2.7 cm to 8.9 cm) 
originating from the muscular layer of the gastrointestinal tract mostly seen in the 
stomach and small bowel but they can be found in any part of the gastrointestinal 
tract. The incidence of GISTs has increased over the last few decades possibly due to 
increased detection due to increased availability of imaging studies, endoscopic and 
endosonographic procedures. C-KIT gene mutation with constitutive activation of 
tyrosine kinase and ICC hyperplasia is the pathogenic mechanism seen in most GISTs. 
Mutation in PDGFRA gene can also lead to the formation of GISTs. The importance of 
PDGFRA mutation (due to Asp842Val substitution in exon18) is that they are resistant 
to imatinib therapy. KIT and PDGFRA mutations are not detectable in 15% of GISTs 
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when they are called wild-type GISTs. Immunohistochemistry is important to 
differentiate GISTs from other mesenchymal tumors like leiomyoma. GISTs stain 
positive for KIT, CD34, CD117 and DOG1. Histologic features of GISTs include spindle 
cell type, epitheloid type or mixed type. GISTs remain silent when they are small in 
size but when they increase in size, they can produce various manifestations which 
include gastrointestinal bleeding, abdominal pain, small bowel obstruction, dysphagia 
and proctalgia depending on their location. CT, MRI, PET/CT, endoscopic procedures 
and EUS are done in the diagnostic and metastatic evaluation as well as in following 
response to treatment. Tissue acquisition is done by EUS FNA/TCB, or post-
operatively or sometimes by percutaneous biopsy in case of metastatic GISTs. Surgery 
is the treatment of choice for any potentially resectable GIST greater than 2 cm in size 
or if the GIST is localized and symptomatic or if the GIST has suspicious malignant 
features on EUS. Type of surgery depends on the location of GISTs. Now there is an 
increased interest in endoscopic resection of gastric GISTs < 4 cm in size, and various 
endoscopic resection methods are available. TKI has multiple roles in the treatment of 
GISTs: (1) As a neoadjuvant therapy preoperatively for 6 to 12 mo for tumor 
cytoreduction of a large GIST to make it operable; (2) As an adjuvant therapy post-
operatively to prevent recurrence of GISTs for a minimum of 3 years; and (3) As a 
neoadjuvant therapy (to be considered) for organ and function-preserving surgeries 
like esophagectomy, pancreatoduodenectomy and abdominoperineal resection for 
esophageal, duodenal and rectal GISTs.
CONCLUSION
GIST is an important gastrointestinal tumor. Although they can be asymptomatic 
when small, they can have a variety of clinical presentations when they are large or 
rapidly growing. They are diagnosed by imaging, endoscopic and endosonographic 
studies or sometimes post-operatively. They have distinct genetic mutations, 
immunohistochemical features and risk stratification criteria. Surgical or endoscopic 
resection and TKI are the main modalities of treatment. Clinical trials are ongoing for 
refractory cases. Future treatment options will change as we discover more and more 
drugs against GISTs.
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